Driven by the strategic acquisition and consolidated contribution of Alvogen US, Lotus Pharmaceutical (美時) reported December revenue of NT$2.442 billion (+67% YoY). This propelled full-year 2025 consolidated revenue past the NT$20 billion mark to reach **NT$20.501 billion (+10% YoY)**, solidifying its position as the revenue leader in Taiwan’s biotech industry.

• Acquisition Impact: 2025 figures include a US$39.5 million contribution from Alvogen US.
• Organic Growth: On a like-for-like basis (excluding Alvogen US and related inter-company eliminations), annual consolidated revenue stood at NT$19.513 billion (+5% YoY).
• Outlook: As integration with Alvogen US continues, Lotus expects to further realize post-merger synergies to drive the next phase of growth.

Resource: 美時2025營收破200億大關 穩坐生技業績龍頭